BRAF p.V600E | Search

Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

878 results for “BRAF p.V600E”

Trials

View all 614 →

Dabrafenib, Trametinib, and IMRT in Treating Patients With BRAF Mutated Anaplastic Thyroid Cancer

6 participants · First posted Jun 5, 2019

Rechallenge of BRAF +/- MEK Inhibitors Following an Adverse Event in Patients With Cancer

16,000 participants · First posted Oct 15, 2021

Active, not recruiting

Adaptive BRAF-MEK Inhibitor Therapy for Advanced BRAF Mutant Melanoma

14 participants · First posted Jun 1, 2018

Drugs

View all 32 →

BRAF-V600E degrader

DPX BRAF/CPA

BRAF kinase inhibitor (Ruga Corporation)

Organizations

BRAC UNIVERSITY

Bangladesh

BRAY GROUP LIMITED

United Kingdom

News

View all 230 →

BRAF p.V600E Mutation Shows Limited Prognostic Value in Papillary Thyroid Cancer Risk Stratification

High Tumor Mutational Burden Linked to Improved Survival in Metastatic Colon Cancer

FDA Approves Novartis' Tafinlar + Mekinist Combo for BRAF V600E-Mutated Solid Tumors

Page 1 of 88